Prognostic Markers for Canine Mast Cell Tumors
Author Information
Author(s): Webster Joshua D, Yuzbasiyan-Gurkan Vilma, Thamm Douglas H, Hamilton Elizabeth, Kiupel Matti
Primary Institution: Michigan State University
Hypothesis
The study aims to evaluate the prognostic utility of various markers in dogs with mast cell tumors treated with vinblastine and prednisone.
Conclusion
The study confirms the prognostic value of histologic grade and c-KIT mutations for canine mast cell tumors and suggests that dogs with grade 3 tumors benefit from postoperative chemotherapy.
Supporting Evidence
- Histologic grade 3 MCTs were associated with decreased disease-free intervals and overall survival.
- Dogs with histologic grade 3 MCT had significantly increased disease-free intervals and overall survival when treated with chemotherapy.
- MCTs with c-KIT mutations tended to have increased disease-free intervals and overall survival when treated with chemotherapy.
Takeaway
This study found that certain tumor characteristics can help predict how well dogs with mast cell tumors will do after treatment, especially those with more aggressive tumors.
Methodology
The study included 28 dogs with mast cell tumors treated with vinblastine and prednisone, evaluating various prognostic markers and comparing outcomes with a control group treated with surgery alone.
Potential Biases
Differences in care between clinicians and hospitals might affect treatment outcomes.
Limitations
The study is retrospective, has small sample sizes in some subgroups, and variations in treatment and staging.
Participant Demographics
14 female and 14 male dogs, aged 2 to 14 years, representing 16 breeds.
Statistical Information
P-Value
p = 0.0220 for DFI, p = 0.010 for OS
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website